135 related articles for article (PubMed ID: 1966986)
1. Metabolism of C3 and factor B in patients with congenital factor I deficiency.
Rasmussen JM; Teisner B; Brandt J; Brandslund I; Gry H
J Clin Lab Immunol; 1990 Feb; 31(2):59-67. PubMed ID: 1966986
[TBL] [Abstract][Full Text] [Related]
2. Three cases of factor I deficiency: the effect of treatment with plasma.
Møller Rasmussen J; Teisner B; Jepsen HH; Svehag SE; Knudsen F; Kirstein H; Buhl M
Clin Exp Immunol; 1988 Oct; 74(1):131-6. PubMed ID: 3219799
[TBL] [Abstract][Full Text] [Related]
3. Requirements for beta1H globulin and C3b inactivator in the control of the alternative complement pathway in human serum.
Whaley K; Thompson RA
Immunology; 1978 Dec; 35(6):1045-9. PubMed ID: 83964
[TBL] [Abstract][Full Text] [Related]
4. The role of immunoglobulins in alternative pathway activation by zymosan. II. The effect of IgG on the kinetics of the alternative pathway.
Schenkein HA; Ruddy S
J Immunol; 1981 Jan; 126(1):11-5. PubMed ID: 6905857
[No Abstract] [Full Text] [Related]
5. Prevention of immune precipitation by purified components of the alternative pathway.
Naama JK; Holme E; Hamilton E; Whaley K
Clin Exp Immunol; 1985 Apr; 60(1):169-77. PubMed ID: 3159522
[TBL] [Abstract][Full Text] [Related]
6. C3 metabolism in a patient with deficiency of the second component of complement (C2) and discoid lupus erythematosus.
Wild JH; Zvaifler NJ; Müller-Eberhard HJ; Wilson CB
Clin Exp Immunol; 1976 May; 24(2):238-48. PubMed ID: 1084239
[TBL] [Abstract][Full Text] [Related]
7. Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.
Ziegler JB; Alper CA; Rosen RS; Lachmann PJ; Sherington L
J Clin Invest; 1975 Mar; 55(3):668-72. PubMed ID: 1117072
[TBL] [Abstract][Full Text] [Related]
8. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
[TBL] [Abstract][Full Text] [Related]
9. Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection.
Alper CA; Abramson N; Johnston RB; Jandl JH; Rosen FS
J Clin Invest; 1970 Nov; 49(11):1975-85. PubMed ID: 4097977
[TBL] [Abstract][Full Text] [Related]
10. Interactions of chrysotile asbestos fibres with the complement system.
Saint-Remy JM; Cole P
Immunology; 1980 Oct; 41(2):431-7. PubMed ID: 6904360
[TBL] [Abstract][Full Text] [Related]
11. Effect of gangliosides on activation of the alternative pathway of human complement.
Michalek MT; Bremer EG; Mold C
J Immunol; 1988 Mar; 140(5):1581-7. PubMed ID: 3346542
[TBL] [Abstract][Full Text] [Related]
12. Stimulation of the intracellular killing of Staphylococcus aureus by monocytes: regulation by immunoglobulin G and complement components C3/C3b and B/Bb.
Leijh PC; van den Barselaar MT; Daha MR; van Furth R
J Immunol; 1982 Jul; 129(1):332-7. PubMed ID: 6979568
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
14. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
Brown EJ; Ramsey J; Hammer CH; Frank MM
J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
[TBL] [Abstract][Full Text] [Related]
15. Alternative pathway complement activation in rheumatoid arthritis.
El-Ghobarey A; Whaley K
J Rheumatol; 1980; 7(4):453-60. PubMed ID: 6158571
[TBL] [Abstract][Full Text] [Related]
16. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
Hiramatsu M; Balow JE; Tsokos GC
J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
[TBL] [Abstract][Full Text] [Related]
17. Alterations in C3 activation and binding caused by phosphorylation by a casein kinase released from activated human platelets.
Ekdahl KN; Nilsson B
J Immunol; 1999 Jun; 162(12):7426-33. PubMed ID: 10358196
[TBL] [Abstract][Full Text] [Related]
18. Assembly of the membrane attack complex promotes decay of the alternative pathway C3 convertase on Neisseria gonorrhoeae.
Densen P; McRill CM; Ross SC
J Immunol; 1988 Dec; 141(11):3902-9. PubMed ID: 3141507
[TBL] [Abstract][Full Text] [Related]
19. Formation in the presence of C3 nephritic factor (C3NeF) of an alternative pathway C3 convertase containing uncleaved B.
Daha MR; Fearon DT; Austen KF
Immunology; 1976 Nov; 31(5):789-96. PubMed ID: 992711
[TBL] [Abstract][Full Text] [Related]
20. Complement activation in Staphylococcus aureus bacteraemia.
Hallett AF; Cooper R
Clin Exp Immunol; 1980 May; 40(2):306-11. PubMed ID: 6904257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
